Is STIM or DCTH more profitable?

Delcath Systems has a net margin of 0.62% compared to Neuronetics' net margin of -24.48%. Delcath Systems' return on equity of 0.51% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -24.48% -139.83% -27.13% Delcath Systems 0.62% 0.51% 0.46%

Do analysts rate CNXU or STIM?

Neuronetics has a consensus price target of $3.00, indicating a potential upside of 125.56%. Given Neuronetics' stronger consensus rating and higher possible upside, analysts clearly believe Neuronetics is more favorable than Conexeu Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Conexeu Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Neuronetics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, CNXU or STIM?

Conexeu Sciences has higher earnings, but lower revenue than Neuronetics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Conexeu Sciences N/A N/A N/A N/A N/A Neuronetics $149.16M 0.62 -$39M -$0.54 N/A

Is CV or STIM more profitable?

Neuronetics has a net margin of -24.48% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -198.87% N/A -136.03% Neuronetics -24.48% -139.83% -27.13%

Is STIM or CARL more profitable?

Neuronetics has a net margin of -24.48% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -24.48% -139.83% -27.13% Carlsmed -57.76% -60.74% -29.84%

Neuronetics (STIM) Competitors

$1.33 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$1.34 +0.01 (+0.75%)

As of 06/12/2026 06:41 PM Eastern

Compare

STIM vs. CLPT, DCTH, CNXU, CV, and CARL

Should you buy Neuronetics stock or one of its competitors? MarketBeat compares Neuronetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neuronetics include ClearPoint Neuro (CLPT), Delcath Systems (DCTH), Conexeu Sciences (CNXU), CapsoVision (CV), and Carlsmed (CARL). These companies are all part of the "medical equipment" industry.

How does Neuronetics compare to ClearPoint Neuro?

ClearPoint Neuro (NASDAQ:CLPT) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

In the previous week, ClearPoint Neuro and ClearPoint Neuro both had 1 articles in the media. Neuronetics' average media sentiment score of 1.89 beat ClearPoint Neuro's score of 1.87 indicating that Neuronetics is being referred to more favorably in the news media.

Company	Overall Sentiment
ClearPoint Neuro	Very Positive
Neuronetics	Very Positive

ClearPoint Neuro has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Neuronetics has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Neuronetics has a net margin of -24.48% compared to ClearPoint Neuro's net margin of -71.57%. Neuronetics' return on equity of -139.83% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-71.57%	-140.96%	-36.98%
Neuronetics	-24.48%	-139.83%	-27.13%

ClearPoint Neuro currently has a consensus target price of $18.00, indicating a potential upside of 33.93%. Neuronetics has a consensus target price of $3.00, indicating a potential upside of 125.56%. Given Neuronetics' higher possible upside, analysts plainly believe Neuronetics is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ClearPoint Neuro has higher earnings, but lower revenue than Neuronetics. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	10.90	-$25.54M	-$1.01	N/A
Neuronetics	$149.16M	0.62	-$39M	-$0.54	N/A

30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by insiders. Comparatively, 8.4% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Neuronetics beats ClearPoint Neuro on 10 of the 15 factors compared between the two stocks.

How does Neuronetics compare to Delcath Systems?

Neuronetics (NASDAQ:STIM) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

53.6% of Neuronetics shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 8.4% of Neuronetics shares are held by insiders. Comparatively, 19.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Delcath Systems had 1 more articles in the media than Neuronetics. MarketBeat recorded 2 mentions for Delcath Systems and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.89 beat Delcath Systems' score of 0.94 indicating that Neuronetics is being referred to more favorably in the media.

Company	Overall Sentiment
Neuronetics	Very Positive
Delcath Systems	Positive

Neuronetics has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

Delcath Systems has a net margin of 0.62% compared to Neuronetics' net margin of -24.48%. Delcath Systems' return on equity of 0.51% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-24.48%	-139.83%	-27.13%
Delcath Systems	0.62%	0.51%	0.46%

Delcath Systems has lower revenue, but higher earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	0.62	-$39M	-$0.54	N/A
Delcath Systems	$85.23M	4.75	$2.70M	$0.01	1,172.00

Neuronetics presently has a consensus price target of $3.00, suggesting a potential upside of 125.56%. Delcath Systems has a consensus price target of $22.50, suggesting a potential upside of 91.98%. Given Neuronetics' higher possible upside, equities research analysts clearly believe Neuronetics is more favorable than Delcath Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Delcath Systems beats Neuronetics on 12 of the 16 factors compared between the two stocks.

How does Neuronetics compare to Conexeu Sciences?

Conexeu Sciences (NASDAQ:CNXU) and Neuronetics (NASDAQ:STIM) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

In the previous week, Conexeu Sciences had 2 more articles in the media than Neuronetics. MarketBeat recorded 3 mentions for Conexeu Sciences and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.89 beat Conexeu Sciences' score of 0.44 indicating that Neuronetics is being referred to more favorably in the news media.

Company	Overall Sentiment
Conexeu Sciences	Neutral
Neuronetics	Very Positive

53.6% of Neuronetics shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Conexeu Sciences has higher earnings, but lower revenue than Neuronetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Conexeu Sciences	N/A	N/A	N/A	N/A	N/A
Neuronetics	$149.16M	0.62	-$39M	-$0.54	N/A

Conexeu Sciences has a net margin of 0.00% compared to Neuronetics' net margin of -24.48%. Conexeu Sciences' return on equity of 0.00% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Conexeu Sciences	N/A	N/A	N/A
Neuronetics	-24.48%	-139.83%	-27.13%

Neuronetics has a consensus price target of $3.00, indicating a potential upside of 125.56%. Given Neuronetics' stronger consensus rating and higher possible upside, analysts clearly believe Neuronetics is more favorable than Conexeu Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Conexeu Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Neuronetics beats Conexeu Sciences on 7 of the 11 factors compared between the two stocks.

How does Neuronetics compare to CapsoVision?

CapsoVision (NASDAQ:CV) and Neuronetics (NASDAQ:STIM) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

CapsoVision presently has a consensus price target of $8.50, suggesting a potential upside of 18.22%. Neuronetics has a consensus price target of $3.00, suggesting a potential upside of 125.56%. Given Neuronetics' higher possible upside, analysts plainly believe Neuronetics is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Neuronetics has a net margin of -24.48% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
Neuronetics	-24.48%	-139.83%	-27.13%

CapsoVision has higher earnings, but lower revenue than Neuronetics. CapsoVision is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	26.51	-$25.32M	-$2.34	N/A
Neuronetics	$149.16M	0.62	-$39M	-$0.54	N/A

In the previous week, CapsoVision had 1 more articles in the media than Neuronetics. MarketBeat recorded 2 mentions for CapsoVision and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.89 beat CapsoVision's score of 1.32 indicating that Neuronetics is being referred to more favorably in the news media.

Company	Overall Sentiment
CapsoVision	Positive
Neuronetics	Very Positive

53.6% of Neuronetics shares are held by institutional investors. 2.3% of CapsoVision shares are held by insiders. Comparatively, 8.4% of Neuronetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Neuronetics beats CapsoVision on 9 of the 15 factors compared between the two stocks.

How does Neuronetics compare to Carlsmed?

Neuronetics (NASDAQ:STIM) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

53.6% of Neuronetics shares are held by institutional investors. 8.4% of Neuronetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Carlsmed had 2 more articles in the media than Neuronetics. MarketBeat recorded 3 mentions for Carlsmed and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.89 beat Carlsmed's score of 0.17 indicating that Neuronetics is being referred to more favorably in the media.

Company	Overall Sentiment
Neuronetics	Very Positive
Carlsmed	Neutral

Neuronetics currently has a consensus target price of $3.00, suggesting a potential upside of 125.56%. Carlsmed has a consensus target price of $19.33, suggesting a potential upside of 69.29%. Given Neuronetics' higher possible upside, analysts plainly believe Neuronetics is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Carlsmed has lower revenue, but higher earnings than Neuronetics. Carlsmed is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	0.62	-$39M	-$0.54	N/A
Carlsmed	$50.51M	6.15	-$29.63M	-$2.51	N/A

Neuronetics has a net margin of -24.48% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-24.48%	-139.83%	-27.13%
Carlsmed	-57.76%	-60.74%	-29.84%

Summary

Neuronetics beats Carlsmed on 9 of the 15 factors compared between the two stocks.

Get Neuronetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STIM vs. The Competition

Export

Metric	Neuronetics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$92.56M	$7.04B	$6.52B	$12.05B
Dividend Yield	N/A	1.21%	2.67%	5.66%
P/E Ratio	-2.46	47.88	24.00	24.42
Price / Sales	0.62	70.95	514.36	111.24
Price / Cash	N/A	25.59	27.48	37.92
Price / Book	3.50	6.84	10.54	6.82
Net Income	-$39M	$159.20M	$3.57B	$337.56M
7 Day Performance	3.91%	-0.93%	0.60%	1.17%
1 Month Performance	3.91%	5.15%	1.56%	3.16%
1 Year Performance	-64.91%	1.23%	25.42%	30.58%

Neuronetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STIM Neuronetics	3.5788 of 5 stars	$1.33 flat	$3.00 +125.6%	-64.9%	$92.56M	$149.16M	N/A	180	Positive News
CLPT ClearPoint Neuro	2.6274 of 5 stars	$12.17 -3.7%	$18.00 +47.9%	+16.5%	$379.07M	$40.61M	N/A	110	Gap Up
DCTH Delcath Systems	2.7568 of 5 stars	$10.47 -1.2%	$22.50 +114.9%	-23.6%	$365.93M	$90.44M	1,049.90	60	Gap Up
CNXU Conexeu Sciences	N/A	$15.77 +11.7%	N/A	N/A	$356.81M	N/A	N/A	4	Short Interest Increase Gap Up High Trading Volume
CV CapsoVision	1.5061 of 5 stars	$6.95 +0.7%	$8.50 +22.3%	N/A	$338.76M	$13.56M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STIM) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neuronetics (STIM) Competitors

STIM vs. CLPT, DCTH, CNXU, CV, and CARL

How does Neuronetics compare to ClearPoint Neuro?

Summary

How does Neuronetics compare to Delcath Systems?

Summary

How does Neuronetics compare to Conexeu Sciences?

Summary

How does Neuronetics compare to CapsoVision?

Summary

How does Neuronetics compare to Carlsmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STIM vs. The Competition

Neuronetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neuronetics (STIM) Competitors

STIM vs. CLPT, DCTH, CNXU, CV, and CARL

How does Neuronetics compare to ClearPoint Neuro?

Does the media refer more to CLPT or STIM?

Which has more volatility and risk, CLPT or STIM?

Is CLPT or STIM more profitable?

Do analysts rate CLPT or STIM?

Which has preferable valuation & earnings, CLPT or STIM?

Do insiders and institutionals believe in CLPT or STIM?

Summary

How does Neuronetics compare to Delcath Systems?

Do insiders & institutionals hold more shares of STIM or DCTH?

Does the media prefer STIM or DCTH?

Which has more volatility & risk, STIM or DCTH?

Is STIM or DCTH more profitable?

Which has preferable valuation & earnings, STIM or DCTH?

Do analysts rate STIM or DCTH?

Summary

How does Neuronetics compare to Conexeu Sciences?

Does the media favor CNXU or STIM?

Do institutionals & insiders have more ownership in CNXU or STIM?

Which has better valuation & earnings, CNXU or STIM?

Is CNXU or STIM more profitable?

Do analysts rate CNXU or STIM?

Summary

How does Neuronetics compare to CapsoVision?

Do analysts rate CV or STIM?

Is CV or STIM more profitable?

Which has higher valuation & earnings, CV or STIM?

Does the media favor CV or STIM?

Do institutionals and insiders hold more shares of CV or STIM?

Summary

How does Neuronetics compare to Carlsmed?

Do insiders and institutionals have more ownership in STIM or CARL?

Does the media refer more to STIM or CARL?

Do analysts prefer STIM or CARL?

Which has preferable valuation & earnings, STIM or CARL?

Is STIM or CARL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STIM vs. The Competition

Neuronetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools